Biogen Inc. Chief Executive Michel Vounatsos will resign from the company as it slims down its workforce, cuts spending by $1 billion annually and attempts to chart a new course after Medicare’s devastating refusal to cover its new Alzheimer’s drug Aduhelm.
Biogen said Tuesday that Mr. Vounatsos would continue to lead the company and remain on its board until a search for a new CEO is completed.
To Read the Full Story
This post first appeared on wsj.com
